Several COVID-19 vaccines have different features but Moderna (MRNA) has emerged as a strong player. Despite some Analysts’ estimates of a drop in earnings, recent trials of mRNA-4157 and Keytruda combination for lung cancer are underway. Moderna is also empowering the next generation by providing a free course on mRNA medicines. There has been a patent dispute between Moderna and GSK over mRNA vaccines. Moderna is due royalties for their mRNA vaccine technology and the US government is supporting Moderna's development of an mRNA bird flu pandemic vaccine. They are also running trials on their First mRNA Mpox Vaccine and mRNA-1273 vaccine for adults. Despite stock setbacks, Moderna has striking plans to expand horizons in Gene Editing and mRNA vaccines. However, there are disputes with other pharmaceutical giants over COVID-19 vaccine patents. Other significant developments include the approval of Moderna's mRNA RSV vaccine for older adults. Moderna's norovirus vaccine has begun Phase III trials, and research for mRNA vaccines for various other diseases are underway. Moderna's future efforts also include the development of an mRNA medicine to treat a devastating childhood disease.
Moderna MRNA News Analytics from Wed, 17 Jan 2024 08:00:00 GMT to Sat, 02 Nov 2024 08:15:41 GMT - Rating 2 - Innovation 7 - Information 8 - Rumor 2
